Novel Pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazoles as Protein Kinase C Inhibitors for Treating Diseases


Citar

Texto integral

Resumo

This patent describes the series of compounds and their pharmaceutically acceptable salts, such as compound K7 (as a representative potent compound). These protein kinase C selective inhibitors are useful for treating diabetes mellitus and its complications, cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease, dermatological disease, virus diseases, inflammatory disorders, or diseases in which the liver is a target organ.

Sobre autores

Surya De

Conju-probe, Conju-probe,

Autor responsável pela correspondência
Email: info@benthamscience.net

Bibliografia

  1. Sipka, S.; Bíró, T.; Czifra, G.; Griger, Z.; Gergely, P.; Brugós, B.; Tarr, T. The role of protein kinase C isoenzymes in the pathogenesis of human autoimmune diseases. Clin. Immunol., 2022, 241, 109071. doi: 10.1016/j.clim.2022.109071 PMID: 35781096
  2. Li, H.; Nukui, S.; Scales, S.A.; Teng, M.; Yin, C. Npyrimidin- 4-yl-3-amino-pyrrolo3,4-cpyrazole derivatives as PKC kinase inhibitors. US Patent, US8877761B2, 2014.
  3. Botrous, I.; Hong, Y.; Li, H.; Liu, K.K.C.; Nukui, S.; Teng, M. 3-amido-pyrrolo3,4-cpyrazole-5(1h, 4h,6h) carbaldehyde derivatives as inhibitors of protein kinase c. European Patent, EP2195321B1, 2016.
  4. Cooke, M.; Kazanietz, M.G. Overarching roles of diacylglycerol signaling in cancer development and antitumor immunity. Sci. Signal., 2022, 15(729), eabo0264. doi: 10.1126/scisignal.abo0264 PMID: 35412850
  5. He, S.; Li, Q.; Huang, Q.; Cheng, J. Targeting protein kinase C for cancer therapy. Cancers , 2022, 14(5), 1104. doi: 10.3390/cancers14051104 PMID: 35267413
  6. Miao, L.; Pan, D.; Shi, J.; Du, J.; Chen, P.; Gao, J.; Yu, Y.; Shi, D.Z.; Guo, M. Role and mechanism of PKC-δ for cardiovascular disease: Current status and perspective. Front. Cardiovasc. Med., 2022, 9, 816369. doi: 10.3389/fcvm.2022.816369 PMID: 35242825
  7. Kawano, T.; Inokuchi, J.; Eto, M.; Murata, M.; Kang, J.H. Activators and inhibitors of protein kinase C (PKC): Their applications in clinical trials. Pharmaceutics, 2021, 13(11), 1748. doi: 10.3390/pharmaceutics13111748 PMID: 34834162
  8. Sharifinejad, N.; Azizi, G.; Behniafard, N.; Zaki-Dizaji, M.; Jamee, M.; Yazdani, R.; Abolhassani, H.; Aghamohammadi, A. Protein Kinase C-Delta defect in Autoimmune Lymphoproliferative syndrome-like disease: First case from the national iranian registry and review of the literature. Immunol. Invest., 2022, 51(2), 331-342. doi: 10.1080/08820139.2020.1829638 PMID: 33047643
  9. Pilo, C.A.; Newton, A.C. Two sides of the same coin: Protein Kinase C β in cancer and neurodegeneration. Front. Cell Dev. Biol., 2022, 10, 929510. doi: 10.3389/fcell.2022.929510 PMID: 35800893
  10. Jalil, S.J.; Sacktor, T.C.; Shouval, H.Z. Atypical PKCs in memory maintenance: The roles of feedback and redundancy. Learn. Mem., 2015, 22(7), 344-353. doi: 10.1101/lm.038844.115 PMID: 26077687
  11. Kadir, R.R.A.; Alwjwaj, M.; Bayraktutan, U. Protein kinase C-β distinctly regulates blood-brain barrier-forming capacity of brain microvascular endothelial cells and outgrowth endothelial cells. Metab. Brain Dis., 2022, 37(6), 1815-1827. doi: 10.1007/s11011-022-01041-1 PMID: 35763197
  12. Zhao, H.; Gong, L.; Wu, S.; Jing, T.; Xiao, X.; Cui, Y.; Xu, H.; Lu, H.; Tang, Y.; Zhang, J.; Zhou, Q.; Ma, D.; Li, X. The inhibition of Protein Kinase Cβ contributes to the pathogenesis of preeclampsia by activating autophagy. EBioMedicine, 2020, 56, 102813. doi: 10.1016/j.ebiom.2020.102813 PMID: 32544612
  13. Starosyla, S.A.; Volynets, G.P.; Protopopov, M.V.; Bdzhola, V.G.; Pashevin, D.O.; Polishchuk, V.O.; Kozak, T.O.; Stroi, D.O.; Dosenko, V.E.; Yarmoluk, S.M. Pharmacophore modeling, docking and molecular dynamics simulation for identification of novel human protein kinase C beta (PKCβ) inhibitors. Struct. Chem., 2022, 2022, 1-15. doi: 10.1007/s11224-022-02075-y PMID: 36248344
  14. Melnyk, J.E.; Steri, V.; Nguyen, H.G.; Hwang, Y.C.; Gordan, J.D.; Hann, B.; Feng, F.Y.; Shokat, K.M. Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKCβ1. Oncogene, 2022, 41(11), 1536-1549. doi: 10.1038/s41388-022-02179-z PMID: 35087237
  15. Renkhold, L.; Kollmann, R.; Inderwiedenstraße, L.; Kienitz, M.C. PKC-isoform specific regulation of receptor desensitization and KCNQ1/KCNE1 K+ channel activity by mutant α1B-adrenergic receptors. Cell. Signal., 2022, 91, 110228. doi: 10.1016/j.cellsig.2021.110228 PMID: 34958868
  16. von Heydebrand, F.; Fuchs, M.; Kunz, M.; Voelkl, S.; Kremer, A.N.; Oostendorp, R.A.J.; Wilke, J.; Leitges, M.; Egle, A.; Mackensen, A.; Lutzny-Geier, G. Protein kinase C-β-dependent changes in the glucose metabolism of bone marrow stromal cells of chronic lymphocytic leukemia. Stem Cells, 2021, 39(6), 819-830. doi: 10.1002/stem.3352 PMID: 33539629
  17. Berardi, D.E.; Ariza Bareño, L.; Amigo, N.; Cañonero, L.; Pelagatti, M.N.; Motter, A.N.; Taruselli, M.A.; Díaz Bessone, M.I.; Cirigliano, S.M.; Edelstein, A.; Peters, M.G.; Diament, M.; Urtreger, A.J.; Todaro, L.B. All-trans retinoic acid and protein kinase C α/β1 inhibitor combined treatment targets cancer stem cells and impairs breast tumor progression. Sci. Rep., 2021, 11(1), 6044. doi: 10.1038/s41598-021-85344-w PMID: 33723318
  18. Isakov, N. Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression. Semin. Cancer Biol., 2018, 48, 36-52. doi: 10.1016/j.semcancer.2017.04.012 PMID: 28571764

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bentham Science Publishers, 2024